The association between MRI texture analysis and chemoradiotherapy outcomes in glioblastoma cases

Aim: Texture analysis can provide additional information regarding tumor heterogeneity and treatment response. The aim of this study was to evaluate whether MRI texture analysis can predict radiotherapy response and survival in glioblastoma patients.Material and Methods: A total of 26 patients with pathologically confirmed glioblastoma who had received curative chemoradiotherapy (60 Gy radiotherapy + temozolomide) underwent contrast-enhanced cranial MRI texture analysis before and after chemoradiotherapy. The region of interest was determined as the active tumor area in post-contrast axial T1 sections. The gray level intensity, standard deviation of histogram, entropy, uniformity, skewness, and kurtosis values were determined by texture analysis.Results: Comparison of the pre- and post-radiotherapy values showed an increase in entropy (6.97±0.37 vs. 7.20±0.30, p = 0.014) and a decrease in uniformity (0.21±0.12 vs.0.16±0.08, p = 0.049). Therefore, radiation therapy was determined to have caused increased heterogeneity in the active tumor region of glioblastoma. The median follow-up was 7.5 [95% confidence interval (1.8-21.63)] months, while the median overall survival was 12.5 [95% confidence interval (4.24-20.81)] months. Young age, high performance statusand low entropy value after radiotherapywere associated with longer survival according to the Kaplan-Meier analysis (p = 0.014, p = 0.031, p = 0.034, respectively).Conclusion: Based on these results,entropy measurements can be recommended for use as a new prognostic factor for glioblastoma.

PDF

___

1. Johnson, DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neuro Oncol 2012;107:359-64.
2. Mazurowski MA, Desjardins A, Malof JM, Imaging descriptors improve the predictive power of survival models for glioblastoma patients. Neuro Oncol 2013;15:1389-94.
3. Stupp R, Mason, MP Van Den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. Brady, L.W., C.A. Perez, and D.E. Wazer, Perez & Brady’s principles and practice of radiation oncology. 2013: Lippincott Williams & Wilkins.
5. Provenzale JM, Ison C, Delong D. Bidimensional measurements in brain tumors: assessment of interobserver variability. AJR Am J Roentgenol 2009;193:515-22.
6. Castellano G, Bonilha L, Li, LM, Texture analysis of medical images. Clin Radiology 2004;59:1061-9. 7.
Just N, Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer 2014;111:2205-13.
8. Yu H, Caldwell C, Mah K, et al., Automated radiation targeting in head-and-neck cancer using region-based texture analysis of PET and CT images. Int J Radiat Oncol Biol Phys 2009;75:618-25.
9. Yip C, Davnall F, Kozarski R, et al., Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. Dis Esophagus 2015;28:172-9.
10. Mattonen SA, Palma DA, Haasbeek CJ, et al. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. Med Phys 2014;41:033502.
11. Hocquelet A, Auriac T, Perier C, et al. Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy. Eur Radiol 2018;28:2801-11.
12. Jalil O, Afaq A, Ganeshan B, et al., Magnetic resonance based texture parameters as potential imaging biomarkers for predicting long-term survival in locally advanced rectal cancer treated by chemoradiotherapy. Colorectal Dis 2017;19:349-62.
13. Zacharaki EI, Wang S, Chawla S, et al. Classification of brain tumor type and grade using MRI texture and shape in a machine learning scheme. Magn Reson Med 2009;62:1609-18.
14. Pallavi T, Prateek P, Lisa R, et al., Texture Descriptors to distinguish Radiation Necrosis from Recurrent Brain Tumors on multi-parametric MRI. Proc SPIE Int Soc Opt Eng 2014;9035:90352B.
15. Wen PY, Macdonald DR, Reardon DA, et al., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
16. Nelson DA, Tan TT, Rabson AB, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes & development 2004;18:2095-107.
17. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25:4033-42.
18. Ng F, Ganeshan B, Kozarski R, et al. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology 2013;266:177-84.
19. Niha Beig, Jay Patel, Prateek Prasanna, et al. Radiogenomic analysis of hypoxia pathway reveals computerized MRI descriptors predictive of overall survival in glioblastoma. In Med Imag 2017.
20. Liu Y, Zhang X, Feng N, et al. The effect of glioblastoma heterogeneity on survival stratification: a multimodal MR imaging texture analysis. Acta Radiol 2018;59:1239-46.
21. Nowell PC, The clonal evolution of tumor cell populations. Sci 1976;194:23-8.
22. Hu LS, Ning S, Eschbacher JM, et al., Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol 2017;19:128-37.
23. Chaddad A, Tanougast C. Extracted magnetic resonance texture features discriminate between phenotypes and are associated with overall survival in glioblastoma multiforme patients. Med Biol Eng Comput 2016;54:1707-18.
24. Lee J, Jain R, Khalil K, et al. Texture feature ratios from relative CBV maps of perfusion MRI are associated with patient survival in glioblastoma. AJNR Am J Neuroradiol 2016;37:37-43.
25. Peng SL, Chen CF, Liu HL, et al., Analysis of parametric histogram from dynamic contrast-enhanced MRI: application in evaluating brain tumor response to radiotherapy. NMR Biomed 2013;26:443-50.